BRIEF—Alligator appoints new chief medical officer

Swedish immuno-oncology company Alligator Bioscience has appointed Sumeet Ambarkhane as chief medical officer.

Dr Ambarkhane joins Alligator from MorphoSys AG, where he served as senior global program medical director, leading clinical development for hemato-oncology programs.

Alligator is working on lead assets mitazalimab, a CD40 agonist currently in Phase II clinical development, and ATOR-1017, a 4-1BB agonist in Phase I trials.

Chief executive Søren Bregenholt said Dr Ambarkhane’s “in-depth expertise in medical science, clinical development, experience from global regulatory submissions, and product registrations will significantly strengthen our efforts to further advance our novel immune-oncology pipeline.”